FDA Adds Context to Valsartan Recalls

The US Food and Drug Administration (FDA) on 13 July announced a recall of certain batches of valsartan tablets because of an impurity, a chemical known as N-nitrosodimethylamine (NDMA). The amounts of NDMA found in the recalled batches of valsartan exceeded acceptable levels.